PharmaCyte director corrects stock option grant

WEINSTEIN ROBERT reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

WEINSTEIN ROBERT reported acquisition or exercise transactions in this Form 4 filing.

PharmaCyte Biotech, Inc. director Robert Weinstein reported a correction to a stock option award. A previously reported Stock Option (Right to Buy) grant dated 2026-03-31 was made in error and has been cancelled, leaving 0 derivative shares transacted and 0 shares remaining from that specific grant.

Insider Trade Summary

Other: 0 shares

Other 1 txn

Insider WEINSTEIN ROBERT

Role Director

Type	Security	Shares	Price	Value
Other	Stock Option (Right to Buy) F1	0	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct)

Footnotes (1)

1. F1. The reported grant was made in error and has been cancelled.

Key Figures

Transaction date: 2026-03-31 Derivative shares transacted: 0 Shares following transaction: 0 +1 more

4 metrics

Transaction date 2026-03-31 Date associated with the corrected stock option grant entry

Derivative shares transacted 0 Stock Option (Right to Buy) shares reported in the transaction

Shares following transaction 0 Derivative shares from this grant held after cancellation

Derivative transaction count 1 Number of derivative security transactions reported in this amendment

Key Terms

Stock Option (Right to Buy), derivative security, transaction code J, Form 4/A

4 terms

Stock Option (Right to Buy) financial

"Security title reported as Stock Option (Right to Buy) for the grant"

derivative security financial

"Recorded as a derivative security linked to PharmaCyte common stock"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

transaction code J regulatory

"Classified under transaction code J for other acquisition or disposition"

Form 4/A regulatory

"Amended insider report filed on Form 4/A for this correction"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PharmaCyte Biotech (PMCB) report about Robert Weinstein's stock option grant?

PharmaCyte Biotech reported that a stock option grant to director Robert Weinstein was made in error and cancelled. The amended disclosure shows 0 derivative shares were transacted and 0 shares remain from that specific Stock Option (Right to Buy) grant.

How many PharmaCyte Biotech (PMCB) shares were affected by the corrected option grant?

The corrected option entry shows 0 derivative shares in the transaction and 0 shares held afterward. This indicates the erroneous Stock Option (Right to Buy) grant has been fully cancelled with no remaining options from that grant.

What type of security is involved in Robert Weinstein's PharmaCyte Biotech (PMCB) report?

The report involves a Stock Option (Right to Buy), categorized as a derivative security linked to PharmaCyte common stock. That specific option grant was later identified as having been made in error and is now reported as cancelled with zero shares.

What transaction code is used in this PharmaCyte Biotech (PMCB) insider update?

The transaction uses code J, described as an other acquisition or disposition event. In this case, the accompanying footnote clarifies that the previously reported stock option grant was erroneous and has been cancelled rather than representing a new acquisition.

Does Robert Weinstein retain any options from the cancelled PharmaCyte Biotech (PMCB) grant?

No, Robert Weinstein reports holding 0 shares from the cancelled option grant. The total shares following the transaction for this Stock Option (Right to Buy) entry are listed as zero, confirming no remaining derivative position from this specific grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEINSTEIN ROBERT

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NEVADA 89169

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/02/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	(1)	03/31/2026(1)		J(1)		0(1)		(1)	(1)	Common Stock(1)	(1)	(1)	0(1)	D

Explanation of Responses:

1. The reported grant was made in error and has been cancelled.

	/s/ Robert Weinstein	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)